Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

被引：0

作者：

Hanfstein, Benjamin ^{[1
]}

Mueller, Martin C. ^{[1
]}

Erben, Philipp ^{[1
]}

Schnittger, Susanne ^{[2
]}

Saussele, Susanne ^{[1
]}

Leitner, Armin ^{[1
]}

Proetel, Ulrike ^{[1
]}

Ehninger, Gerhard ^{[3
]}

Hossfeld, Dieter K.

Kolb, Hans-Jochem ^{[4
,7
]}

Krause, Stefan W. ^{[5
]}

Nerl, Christoph ^{[6
]}

Pralle, Hans

Heim, Dominik ^{[8
]}

Baerlocher, Gabriela M.

Heimpel, Hermann ^{[9
]}

Hehlmann, Ruediger ^{[1
]}

Hochhaus, Andreas ^{[10
]}

机构：

[1] Univ Heidelberg, Med Fak Mannheim, Med Klin 3, D-6800 Mannheim, Germany

[2] MLL, Munich, Germany

[3] Univ Klinikum Carl Gustav Carus Dresden, Med Klin & Poliklin 1, Dresden, Germany

[4] Klinikum Univ Munchen Grosshadern, Med Klin & Poliklin 3, Munich, Germany

[5] Univ Klinikum Erlangen, Med Klin 5, Erlangen, Germany

[6] Krankenhaus Munchen Schwabing, Munich, Germany

[7] Univ Giessen, Giessen, Germany

[8] Univ Spital Basel, Dept Hematol, Basel, Switzerland

[9] Univ Ulm Klinikum, Innere Med Klin 3, Ulm, Germany

[10] Univ Klinikum Jena, Innere Med Klin 3, Jena, Germany

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：162 / 163

页数：2

共 50 条

[1] Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients - a Follow-up Analysis of the German CML Study IV
Hanfstein, Benjamin
Mueller, Martin C.
Erben, Philipp
Lauseker, Michael
Saussele, Susanne
Proetel, Ulrike
Schnittger, Susanne
Haferlach, Claudia
Kolb, Hans-Jochem
Krause, Stefan W.
Nerl, Christoph
Heim, Dominik
Baerlocher, Gabriela M.
Schubert, Joerg E. A.
Einsele, Hermann
Haenel, Mathias
Dengler, Jolanta
Falge, Christiane
Kanz, Lothar
Neubauer, Andreas
Kneba, Michael
Stegelmann, Frank
Pfreundschuh, Michael
Waller, Cornelius F.
Pfirrmann, Markus
Hasford, Joerg
Hofmann, Wolf-Karsten
Hehlmann, Ruediger
Hochhaus, Andreas
BLOOD, 2011, 118 (21) : 355 - 356
[2] Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia-An Interim Analysis of the Randomized German CML Study IV
Mueller, Martin C.
Hanfstein, Benjamin
Erben, Philipp
Schnittger, Susanne
Saussele, Susanne
Leitner, Armin
Proetel, Ulrike
Lauseker, Michael
Pfirrmann, Markus
Ehninger, Gerhard
Fischer, Thomas
Hasford, Joerg
Hossfeld, Dieter K.
Kolb, Hans Jochem
Krause, Stefan W.
Nerl, Christoph
Pralle, Hans
Gratwohl, Alois
Tobler, Andreas
Hchlmann, Ruediger
Hochhaus, Andreas
BLOOD, 2008, 112 (11) : 129 - 129
[3] CHRONIC MYELOID LEUKEMIA IN THE IMATINIB ERA: THE PREDICTIVE VALUE OF OPTIMAL RESPONSE AT 12 MONTHS OF THERAPY ON ACHIEVING MOLECULAR RESPONSE AND DISEASE PROGRESSION
Santos-Sousa, P.
Guerra, L.
Gomez, B.
Valle, S.
Lopes, C.
Raposo, J.
Martins, C.
Costa, M. J.
Esteves, G.
Fajardo, J.
Lacerda, J. Forjaz
Matos, S.
Santos, S.
do Carmo, J. Alves
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 536 - 537
[4] Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Shah, Neil P.
Guilhot, Francois
Cortes, Jorge E.
Schiffer, Charles A.
le Coutre, Philipp
Bruemmendorf, Tim H.
Kantarjian, Hagop M.
Hochhaus, Andreas
Rousselot, Philippe
Mohamed, Hesham
Healey, Diane
Cunningham, Michael
Saglio, Giuseppe
BLOOD, 2014, 123 (15) : 2317 - 2324
[5] Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure
Shan, J.
O'Brien, S. M.
Garcia-Manero, G.
Faderl, S.
Ravandi, F.
Jabbour, E.
Cortes, J. E.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[6] Long-term follow-up after stem cell transplantation for chronic myeloid leukemia in 1st chronic phase
Yeshurun, M
Guardiola, P
Devergie, A
Ades, L
Ribaud, P
Esperou, H
Gluckman, E
Socié, G
BONE MARROW TRANSPLANTATION, 2003, 31 : S19 - S19
[7] Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up
Do, Young Rok
Kim, Hawk
Kwak, Jae-Yong
Kim, Jeong-A
Kim, Hyeoung-Joon
Park, Joon Seong
Chung, Jooseop
Shin, Ho-Jin
Kim, Sung-Hyun
Bunworasate, Udomsak
Choi, Chul Won
Comia, Narcisa Sonia Cornejo
Zang, Dae Young
Oh, Sukjoong
Jootar, Saengsuree
Reksodiputro, Ary Harryanto
Lee, Won-Sik
Mun, Yeung-Chul
Kong, Jee Hyun
Caguioa, Priscilla B.
Park, Jinny
Jung, Chul W.
Kim, Dong-Wook
BLOOD, 2017, 130
[8] A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.
Ayoubi, Mohamad
Kantarjian, Hagop M.
Wierda, William
Ferrajoli, Alessandra
Hiteshew, Jody
Estrov, Zeev
Cortes-Franco, Jorge
BLOOD, 2009, 114 (22) : 862 - 863
[9] Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy
Alattar, Mona Lisa
Cortes, Jorge E.
O'Brien, Susan
Garcia-Manero, Guillermo
Faderl, Stefan
Ravandi, Farhad
Jabbour, Elias
Shan, Jianqin
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1182 - 1182
[10] Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
Kantarjian, Hagop
O'Brien, Susan
Garcia-Manero, Guillermo
Faderl, Stefan
Ravandi, Farhad
Jabbour, Elias
Shan, Jianqin
Cortes, Jorge
CANCER, 2012, 118 (12) : 3116 - 3122

← 1 2 3 4 5 →